Keyphrases
Adjuvant Therapy
14%
Alpha-fetoprotein
57%
Antitumor Effect
42%
Antitumor Efficacy
14%
Autologous T Cell
14%
Cancer Causes
14%
Cancer Mortality
14%
CD-8
14%
CD8+ T Cells
14%
Clinical Trials
42%
Common Cancers
14%
Concrete Research
14%
Cross-reactivity
14%
Drug Trials
14%
Epitope-specific T Cells
14%
Fast-growing
14%
Functional Avidity
14%
Health Problems
14%
Hepatocellular Carcinoma
100%
Hepatocellular Carcinoma Cells
14%
High Affinity
28%
HLA Haplotypes
14%
HLA-A2
14%
Human alpha-fetoprotein
14%
Immunization Strategy
14%
In Vivo Antitumor Activity
14%
Incidence Rate
14%
Liver Cancer
57%
Liver Resection
14%
Methodical Approach
14%
Most Common Cause
14%
New Drugs
14%
New Therapeutic Approaches
14%
No Toxicity
14%
Novel Therapies
14%
Off-target Toxicity
14%
Primary T Cells
14%
Recurrence Rate
14%
Specific Immunotherapy
14%
Specific Intent
14%
Specific T Cells
14%
Stemness
14%
T Cell Receptor
100%
T Cell Receptor Engineering
100%
T Cells
100%
T-cell Receptor Gene
28%
T-cell Receptor Repertoire
14%
Tumor Cells
14%
Tumor Immunotherapy
14%
Medicine and Dentistry
Adjuvant Therapy
9%
Alpha-Fetoprotein
45%
Cancer Immunotherapy
9%
Cancer Mortality
9%
Carcinoma Cell
9%
CD8 Antigen
18%
Clinical Trial
27%
Cross Reaction
9%
Diseases
9%
Drug Screening
9%
Epitope
9%
Haplotype
9%
Hepatectomy
9%
Hepatocellular Carcinoma
100%
Immunotherapy
100%
Liver Cancer
36%
Malignant Neoplasm
18%
Receptor Gene
18%
Recurrence Risk
9%
T Cell
100%
T Cell Receptor
81%
T Lymphocyte Receptor
100%
Tumor Cell
9%
Pharmacology, Toxicology and Pharmaceutical Science
Alpha Fetoprotein
45%
Cancer Mortality
9%
CD8 Antigen
18%
Clinical Trial
27%
Diseases
9%
Drug Screening
9%
Epitope
9%
Immunotherapy
100%
Liver Cancer
36%
Liver Cell Carcinoma
100%
Malignant Neoplasm
18%
Neoplasm
18%
Recurrence Risk
9%
T Lymphocyte Receptor
100%